8-K: McKesson Q1 Revenue Jumps 23%, Raises FY26 EPS Guidance

McKesson Corporation reported strong first-quarter fiscal 2026 results with record revenue growth and raised its full-year adjusted earnings per diluted share guidance.

Summary

• Consolidated revenues reached a record $97.8 billion, marking a 23% increase compared to the prior year.
• GAAP Earnings per diluted share decreased by $0.75 (11%) to $6.25, primarily due to a $189 million pre-tax provision for bad debts related to the Rite Aid bankruptcy.
• Adjusted Earnings per Diluted Share increased 5% to $8.26, driven by strong operational growth across the business.
• McKesson completed the acquisition of an 80% controlling interest in PRISM Vision Holdings, LLC on April 1, 2025, and a 70% controlling interest in Core Ventures on June 2, 2025, expanding oncology and specialty solutions.
• The Board of Directors approved a 15% increase to the quarterly dividend, raising it to $0.82 per share, marking the ninth consecutive year of dividend increases.
• Fiscal 2026 Adjusted Earnings per Diluted Share guidance range was raised to $37.10 to $37.90, up from the previous range of $36.90 to $37.70, indicating 12% to 15% growth compared to the prior year.
• The company returned $671 million of cash to shareholders, including $581 million in common stock repurchases and $90 million in dividend payments.
• McKesson reported negative Free Cash Flow of $1.1 billion for the first three months of the fiscal year, primarily due to $3.4 billion used for acquisitions.
• An agreement was entered into on August 4, 2025, to sell the retail and distribution businesses in Norway to NorgesGruppen, subject to customary closing conditions and regulatory approvals.

Sentiment

Score: 8

Explanation: The filing indicates strong operational performance with record revenue growth and increased adjusted earnings per share. The raised full-year guidance and consistent dividend increases reflect management's confidence and commitment to shareholder value. While GAAP EPS decreased due to a one-time bad debt provision and free cash flow was negative due to significant acquisition spending, these are largely offset by the strategic growth initiatives and overall positive outlook.

Positives

• Record consolidated revenues of $97.8 billion, a 23% increase year-over-year, driven by strong segment performance and acquisitions.
• Adjusted Earnings per Diluted Share increased 5% to $8.26, reflecting robust operational growth across the business.
• Raised Fiscal 2026 Adjusted Earnings per Diluted Share guidance to $37.10-$37.90, indicating 12% to 15% growth (14% to 17% excluding prior year equity investment gains), signaling increased confidence in future profitability.
• Completed strategic acquisitions of PRISM Vision Holdings, LLC and Core Ventures, significantly expanding differentiated capabilities in Oncology and Specialty solutions.
• The Board of Directors approved a 15% increase to the quarterly dividend, to $0.82 per share, marking the ninth consecutive year of increases, demonstrating commitment to shareholder returns.
• U.S. Pharmaceutical segment revenues increased 25% to $90.0 billion, driven by increased prescription volumes and growth in oncology and specialty products.
• Prescription Technology Solutions segment revenues increased 16% to $1.4 billion, with Adjusted Segment Operating Profit up 21% to $269 million due to higher demand for access solutions.
• Medical-Surgical Solutions segment Adjusted Segment Operating Profit increased 22% to $244 million, led by operational efficiencies from cost optimization initiatives.
• Returned $671 million of cash to shareholders through common stock repurchases ($581 million) and dividend payments ($90 million).

Negatives

• GAAP Earnings per diluted share decreased 11% to $6.25, down $0.75 from $7.00 a year ago.
• A pre-tax increase to the provision for bad debts of $189 million was recorded within the U.S. Pharmaceutical segment related to the Rite Aid bankruptcy.
• Negative Free Cash Flow of $1.1 billion for the first three months of the fiscal year, primarily due to significant cash used for acquisitions.
• Used $3.4 billion of cash towards acquisitions during the quarter, contributing to the negative free cash flow.
• International segment Adjusted Segment Operating Profit decreased 3% to $99 million, partially due to the fiscal 2025 divestiture of Canada-based Rexall and Well.ca retail businesses.

Risks

• Experience costly and disruptive legal disputes and settlements, including regarding the role in distributing controlled substances such as opioids.
• Experience losses not covered by insurance or indemnification.
• Subject to frequently changing, extensive, complex, and challenging healthcare and other laws.
• From time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets.
• Experience cybersecurity incidents that might significantly compromise technology systems or might result in material data breaches.
• Experience significant problems with information systems or networks.
• May be unsuccessful in achieving strategic growth objectives.
• May be unsuccessful in efforts to implement initiatives to reduce or optimize costs.
• Might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted.
• May not receive anticipated benefits from acquisitions or other strategic transactions.
• Might be adversely impacted by delays or other difficulties with divestitures.
• Impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies (e.g., Rite Aid).
• Contracts with government entities involve future funding and compliance risks.
• Might be harmed by changes in relationships or contracts with suppliers.
• Use of third-party data is subject to risks and limitations that could impede the growth of data services business.
• Might be unable to successfully recruit and retain qualified employees.
• Might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
• Might be adversely impacted by competition and industry consolidation.
• Adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes.
• Adversely impacted as a result of distribution of generic pharmaceuticals.
• Adversely impacted by changes in the economic environments in which operations occur.
• Changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for the company and its customers and suppliers, and might impair the financial soundness of customers and suppliers.
• Might be adversely impacted by changes in tax legislation or challenges to tax positions.
• Might be adversely impacted by conditions and events outside of control, such as widespread public health issues, natural disasters, and geopolitical factors.
• May be adversely affected by global climate change or by regulatory or market responses to such change.
• Evolving expectations and regulatory requirements related to governance and sustainability matters, including those concerning human capital management, climate change, environmental responsibility, and social impact may have an adverse effect on business, financial condition, and results of operations and damage reputation.

Future Outlook

McKesson raised its fiscal 2026 Adjusted Earnings per Diluted Share guidance range to $37.10 to $37.90, up from the previous range of $36.90 to $37.70. This updated guidance indicates 12% to 15% growth compared to the prior year, or 14% to 17% growth excluding fiscal 2025 net gains from McKesson Ventures' equity investments. The guidance includes approximately $0.20 of Adjusted Earnings per Diluted Share accretion from the anticipated held-for-sale accounting related to the agreement to sell its retail and distribution businesses in Norway.

Management Comments

• "McKesson had a standout quarter with momentum and growth across the enterprise."
• "We continue to execute against our strategy, delivering for our customers, partners, and patients."
• "Our strong first quarter results included record revenue of $97.8 billion, representing 23% growth compared to the previous year."
• "In addition, we closed the acquisitions of PRISM Vision Holdings and Core Ventures, further expanding our differentiated capabilities in Oncology and Specialty solutions."
• "As a result of the strong first quarter performance and our confidence in the outlook for the remainder of the year, which includes the announced sale of our Norwegian businesses, we are raising our fiscal 2026 Adjusted Earnings per Diluted Share guidance to a range of $37.10 to $37.90."
• "I want to thank our employees for their unwavering dedication and commitment. Their execution and shared focus on our mission have been instrumental in driving performance and creating sustainable value for our stakeholders."

Industry Context

McKesson operates as a diversified healthcare services leader, deeply integrated into the pharmaceutical and medical supply chain. The strong revenue growth, particularly in U.S. Pharmaceutical and Prescription Technology Solutions, reflects robust demand for prescription volumes and specialty products, aligning with broader trends of increasing healthcare expenditure and the growing complexity of drug distribution. The strategic acquisitions in oncology and specialty solutions (PRISM Vision Holdings, Core Ventures, and expansion of The US Oncology Network) indicate a focus on high-growth, high-margin areas within healthcare, consistent with industry shifts towards specialized care and value-based models. The divestiture of Norwegian retail and distribution businesses suggests a strategic streamlining of international operations to focus on core strengths or more profitable regions.

Comparison to Industry Standards

• McKesson's 23% consolidated revenue growth significantly outpaces the typical single-digit growth seen in mature pharmaceutical distribution and healthcare services sectors, suggesting strong market share gains or successful integration of recent acquisitions. For example, competitors like Cardinal Health and AmerisourceBergen typically report revenue growth in the low to mid-single digits, making McKesson's performance notable.
• The expansion of The US Oncology Network to approximately 3,300 providers through the Core Ventures acquisition strengthens McKesson's position in the oncology market, a high-growth segment. This network is a key differentiator compared to general distributors and positions McKesson similarly to integrated healthcare providers or specialized group purchasing organizations.
• The 15% dividend increase for the ninth consecutive year demonstrates a strong commitment to shareholder returns and financial stability, often a benchmark for mature, cash-generative companies in the healthcare sector.
• The negative Free Cash Flow of $1.1 billion, while concerning on its own, is largely attributable to $3.4 billion in cash used for acquisitions, which is a strategic investment rather than an operational weakness. This indicates a company actively deploying capital for growth, which can be a positive sign if the acquisitions are accretive and well-integrated, contrasting with companies that might have negative free cash flow due to operational inefficiencies.

Legal Proceedings

• The company experiences costly and disruptive legal disputes and settlements, including regarding its role in distributing controlled substances such as opioids.
• Adjustments to certain reserves, including those related to estimated probable settlements for controlled substance monitoring and reporting, and opioid-related claims.
• A pre-tax provision for bad debts of $189 million was recorded within the U.S. Pharmaceutical segment related to the bankruptcy of customer Rite Aid Corporation.

Stakeholder Impact

• Shareholders: Positive impact due to increased dividend, share repurchases, raised EPS guidance, and strategic acquisitions aimed at long-term growth.
• Customers: Enhanced service offerings and expanded capabilities, particularly in oncology and specialty solutions, through recent acquisitions.
• Employees: Acknowledged by the CEO for their unwavering dedication and commitment in driving performance; potential for integration challenges with newly acquired entities.
• Suppliers: Continued strong demand for products, especially in the U.S. Pharmaceutical segment, driven by increased prescription volumes.
• Creditors: Negative free cash flow and significant cash used for acquisitions might be a point of attention, but overall strong revenue and adjusted profit suggest capacity to manage debt obligations.

Next Steps

• Conference call on August 6, 2025, at 4:30 PM ET to discuss financial results.
• McKesson Investor Day on Tuesday, September 23, 2025, featuring presentations by McKesson's leadership team and a live Q&A session.
• Closing of the sale of Norwegian retail and distribution businesses to NorgesGruppen, subject to customary closing conditions and required regulatory approvals.

Key Dates

Recommendation

The company delivered robust revenue growth and a significant increase in adjusted earnings per share, exceeding expectations and leading to a raised full-year guidance. Strategic acquisitions in high-growth areas like oncology and specialty solutions position the company for continued expansion. The consistent dividend increases and share repurchases demonstrate a strong commitment to shareholder returns. While a one-time bad debt provision and acquisition-related cash outflow impacted GAAP earnings and free cash flow, these are largely non-recurring or growth-oriented investments. The underlying operational strength and positive outlook make this a compelling investment opportunity.

Keywords

Healthcare, Pharmaceutical Distribution, Specialty Pharmacy, Oncology, Medical-Surgical, Technology Solutions, Supply Chain, Drug Distribution, Dividend, Acquisitions, Earnings Guidance, McKesson